Subsequent Treatment Choices for Patients with Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer: Restore after a Drug Holiday or Switch to another EGFR-TKI?

Abstract

The outcomes of first-generation EGFR-TKIs (Gefitnib and Erlotinib) have shown great advantages overtraditional treatment strategies in patients with non-small cell lung cancer (NSCLC), but unfortunately wehave to face the situation that most patients still fail to respond in the long term despite initially good control.Up to now, the mechanism of acquired resistance to EGFR-TKIs has not been fully clarified. Herein, we soughtto compile the available clinical reports in the hope to better understanding the subsequent treatment choices,particularly on whether restoring after a drug holiday or switching to another EGFR-TKI is the better optionafter failure of one kind of EGFR-TKI.